TG-1 * Transgallaxys Forum 1

Pages: [1]

Author Topic: Introduction of life-saving pneumococcal vaccine for 1.3 mio infants in Sudan  (Read 1530 times)


  • Jr. Member
  • *
  • Posts: 1121


Three weeks, three countries, three new vaccines

 Life-saving vaccines have been added to children's immunisation cards in three countries in 21 days thanks to the support of GAVI and its partners
21 August 2013
Indonesia, pentavalent vaccine
Children across 6,000 islands will receive five-in-one vaccine

19 August 2013
The Gambia, rotavirus vaccine
Pictures of first babies to get protection from cause of fatal diarrheoa

2 August 2013
Sudan, pneumococcal vaccine
Fighting three of the major killers among infants in Sudan

Indonesia introduces five-in-one vaccine for children

Country has ambitious plan to reach all children by end of 2014

Pentavalent vaccines produced by Indonesian manufacturer Bio Farma, ready to be used to protect Indonesian children from five serious diseases.
GAVI Alliance/Dian Estey/2013

Jakarta, Indonesia, 22 August 2013 – Children across Indonesia are set to be protected from five major childhood diseases through the pentavalent vaccine thanks to an ambitious plan to reach children across the country’s 6,000 inhabited islands by the end of next year.

GAVI is supporting Indonesia’s plan to introduce the vaccine nationwide as quickly as possible. The country expects the vaccine to reach children nationwide by the end of 2014 - almost half the time taken for a previous national vaccine introduction.
Indonesian innovation

The pentavalent vaccine will be purchased from Bio Farma, a national vaccine supplier based in Bandung, 100 miles from the capital Jakarta, meaning that Indonesian children will benefit from Indonesian innovation. Distribution trucks are already transporting vaccine stocks from Bio Farma’s plant to regional cold store rooms ready for delivery across many of Indonesia’s most remote areas.

The vaccine, which contains five antigens in one shot and protects against diphtheria-tetanus-pertussis (DTP), hepatitis B and Haemophilius influenzae type b (Hib), reduces the number of separate injections required for protection and minimises the number of health centre visits required. Indonesia previously used tetravalent which does not protect against Hib.

Launch event

GAVI Deputy CEO Helen Evans visiting Bio Farma's headquarters on 21 August. GAVI Alliance/Dian Estey/2013

Indonesian Minister of Health HE Nafsiah Mboi was joined by Helen Evans, deputy CEO of the GAVI Alliance, at a launch event hosted by Dr H. Ade Swara, MH, Mayor of Karawang District.

Angela Kearney and Dr Khanchit Limpakarnjanarat from GAVI Alliance partners UNICEF and WHO also took part in the ceremony and James Gilling, Head of AusAID Indonesia and Australian Ambassador for HIV/AIDS, Tuberculosis and Malaria, spoke on behalf of GAVI donors.

Strong political will

"With strong political will, Indonesia is making strides towards improving its routine immunisation programme and making it sustainable in the long term," said Helen Evans. "The Minister has rightly set an ambitious target for children in all parts of Indonesia to have access to the five-in-one pentavalent vaccine by the end of next year."

Poorest and hardest to reach children

Let us use the opportunity of the introduction of pentavalent vaccine to reach the poorest and hardest to reach children and protect them from preventable deaths and suffering.

Angela Kearney, UNICEF's Country Representative

"UNICEF is pleased to continue its support to the Government of Indonesia for the introduction of new vaccines", said Angela Kearney, UNICEF's Country Representative.

"Despite immunisation programmes being in place for several decades, children in Indonesia continue to suffer and die from vaccine preventable diseases. Let us use the opportunity of the introduction of pentavalent vaccine to reach the poorest and hardest to reach children and protect them from preventable deaths and suffering."

Sustainable approach

"We applaud the collaborative and sustainable approach taken by Indonesia to develop and introduce pentavalent vaccine," said Dr Khanchit Limpakarnjanarat, WHO’s Country Representative.

"It is one of many powerful and safe vaccines commercially available to countries that can reduce childhood deaths and disability. We hope this is the beginning of a new era in public health in Indonesia where highly cost-effective vaccines play an expanded role in reaching the country's millennium development goals."
Phase introduction

The Government plans to introduce the vaccine in three phases.

Four provinces will begin immunising children immediately, a further nine provinces will begin in January 2014 and the rest of the country will begin their pentavalent programmes in July 2014.
GAVI support

GAVI has provided US$ 57m to support immunisation in Indonesia since 2002.

Key results include the upgrading of cold storage and vaccine delivery networks and helping to introduce hepatitis B monovalent vaccine into the routine immunisation programme.

The introduction of pentavalent represents an essential step towards achieving Millennium Development Goal 4; reducing global under-five mortality rate by two thirds by 2015. GAVI aims to provide funding to increase coverage to 85% by 2020. To achieve this, GAVI will have supported the immunisation of 550 million children with pentavalent vaccine between 2001 and 2020.

GAVI is funded by governments [Australia, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Luxembourg, Netherlands, Norway, Republic of Korea, Russia, South Africa, Spain, Sweden, United Kingdom, United States], the European Commission, the Bill & Melinda Gates Foundation, as well as private and corporate partners [Absolute Return for Kids, Anglo American plc., The Children’s Investment Fund Foundation, Comic Relief, Dutch Postcode Lottery, His Highness Sheikh Bin Zayed Al Nahyan, JP Morgan, “la Caixa” Foundation, LDS Charities and Vodafone].

Click to view the full donor list.
Media requests:

Rob Kelly
GAVI Alliance
+41 79 745 2031
+41 22 909 2978

The Gambia adds rotavirus to children's immunisation cards

The Gambia has become the 15th country to introduce rotavirus vaccine into its routine immunisation schedule with GAVI funding support, part of a global acceleration in the introduction of life-saving vaccines. These images show the first children to be immunised against the most common cause of severe diarrhoea at a special launch ceremony at Kanifing municipal council in western Gambia.
19 August 2013

“I’m proud to be the mother of the first baby in The Gambia to be immunised against rotavirus,” said Amie Samba, cradling her son Mohammed Joof.  “I will make sure that my family and friends know about it and encourage those with young children to have them immunised.”



Introduction of life-saving pneumococcal vaccine targets 1.3 million infants in Sudan

Sudanese children have begun receiving pneumococcal vaccine that will protect them from a leading cause of pneumonia, the biggest killer of children under five in low income countries (Joint news release: GAVI Alliance/UNICEF/WHO)

The first two infants to receive the PCV13 vaccine, held by the WHO representative Dr Anshu Banerjee (right) and the Local Commissioner (left) in Gabal Awlia, near Khartoum.

Khartoum, Geneva, New York, 2 August 2013 - Some 1.3 million infants in Sudan are being targeted in a nationwide pneumococcal conjugate (PCV13) vaccination programme, which commenced on Thursday.

The vaccine will address three of the major killers among infants in Sudan - pneumonia, meningitis, as well septicemia.

The Ministry of Health with support from GAVI Alliance, World Health Organization (WHO), and UNICEF, decided to introduce the pneumococcal vaccine into the routine expanded programme on immunisation after reviewing local surveillance data and WHO position papers recommending global use of the new vaccine. Sudan joined the Regional Surveillance Network for bacterial meningitis in 2007.

Major killer

Pneumococcal disease is an infection caused by the bacteria Streptococcus pneumoniae that causes several serious illnesses, including: bacterial meningitis, pneumonia, otitis media or an inner ear infection, bacteremia, as well as sinus infections. Infection with pneumococcus is a major cause of morbidity and mortality worldwide.

In Sudan, the incidence of pneumonia among under five children is 19% and it represents 27% of hospital admission causes. Pneumonia is also responsible for 10% of hospital deaths among under-five children, and is the second major cause of death after septicemia.

We hope to reach infants even in areas challenged by security issues. We cannot compromise lives especially those of children

Dr Anshu Banerjee, WHO Representative in Sudan Progress

Today's event represents a major step forward in Sudan's efforts to improve the health of its future generations. With GAVI Alliance support since 2001, Sudan has been able to introduce various vaccines against childhood diseases, including hepatitis B, Haemophilius influenzae type b and rotavirus.

WHO and UNICEF are committed to decreasing disabilities and deaths from vaccine preventable diseases, a shared major strategic objective with the Ministry of Health.

Reaching every child

"We hope to reach infants even in areas challenged by security issues. We cannot compromise lives especially those of children. With support from Government and partners, we will work to make sure that no single child in this country will be deprived from vaccination," WHO Representative in Sudan Dr Anshu Banerjee said.

Every Sudanese child has a right to health and the best possible start in life. The PVC13, along with the full regime of life-saving vaccines, is a key intervention to make sure that children are indeed given the best possible start and a fighting chance to survive in good health.

"Like WHO, UNICEF is committed to support the Government and people of Sudan to make sure that every child is reached with vaccination services", said Mr Geert Cappelaere, UNICEF Representative for Sudan.

A comprehensive plan for the introduction of the new vaccine has been developed covering all components related to vaccination strategy, along with vaccine management, monitoring & evaluation, and financing. A Post Introduction Evaluation will be conducted by WHO, UNICEF and other implementing partners.
« Last Edit: September 11, 2013, 10:08:28 AM by ama »
Pages: [1]